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Accepted 22 January 2014Acute myelogenous leukemia (AML) in patients over age
60 is typically characterized by a distinct proﬁle of adverse
cytogenetic and molecular features. Often associated with
antecedent hematological disorders and/or exposure to prior
cytotoxic chemotherapy, AML in older patients most often is
associated with high-risk karyotype or the expression of
mutated FLT3, KIT, and other molecular markers that explain
both the poor response to induction chemotherapy and
the high rate of relapse that previously had been attributed
to clinical variables alone [1-4]. Allogeneic transplantation
of histocompatible hematopoietic progenitor cells has been
the only approach that seems to improve what would
certainly be a dismal outcome after conventional induction
and consolidation chemotherapy for these older patients
with adverse AML biology [5-7]. Improvements in identi-
fying a histocompatible donor from an enlarged donor base,
the ability to deliver dose-adjusted preparative conditioning
to a more diverse group of older patients with comorbid
medical illness, and improvements in the prevention of
treatment-related complications have all made trans-
plantation a potential postremission strategy for older pa-
tients with high-risk AML [7]. Transplantation, however, is
still feasible for only a fraction of patients because failure of
induction chemotherapy, early relapse, signiﬁcant organ
dysfunction, and frailty deﬁne a large segment of the older
population for whom transplantation is not even considered.
However one deﬁnes “elderly,” the distribution of adverse
biologic features increases in each progressive age cohort of
patients with AML. Even in the absence of high-risk cytoge-
netics and adverse molecular features, advanced age at diag-
nosis is associated with resistance to leukemia treatment.
Comorbid medical conditions, no doubt, contribute to treat-
ment failure, but even in the absence of identiﬁed organ
dysfunction, clinical resistance to leukemia treatment is
generally the rule among older patients. Despite trials of novel
agents, there has been no regulatory pathway for treatments
that target high-risk AML based on clinical criteria, such as
advanced age. Clofarabine, laromustine, gemtuzumab, and
tipifarnib have all been investigated as single agents for AMLFinancial disclosure: See Acknowledgments on page 438.
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encouraging results in terms of remission were not converted
to improved survival, the end point required for approval. One
problem that has plagued the development of these and other
novel agents that target a speciﬁc population is this regulatory
requirement for survival advantage over standard therapy.
Uncertainty about the best postremisison strategy can render
any study of novel induction unsuccessful [10]. Without
deﬁning a postremission therapy of choice, a better induction
regimen may not yield a survival advantage because of the
impact of postremission therapy, and one suspects that
consolidation with allogeneic transplantation would likewise
fail to show a signiﬁcant improvement in survival if all po-
tential subjects were analyzed fromdiagnosis, rather than from
the achievement of complete remission. Even more chal-
lenging is the development of a suitable approach for relapsed
AML, where variation in response rates can be attributed to
signiﬁcant clinical and biological heterogeneity. Further, prior
therapy may adversely affect the tolerance to any novel agent
and may impact treatment-related mortality even later, when
consolidative allogeneic transplantation in second complete
remission (CR2) is contemplated. End points such as achieve-
ment of second remission and bridge-to-transplantation have
not been veriﬁed as surrogates for survival.
In the manuscript by Dr. Michelis et al. from the Princess
Margaret Cancer Centre, the impact of allogeneic trans-
plantation on survival is assessed for patients whose disease
had responded to induction or salvage therapy [11]. Survival
was not assessed for all consecutive older patients admitted
for AML therapy. Even allowing for bias that may occur when
one selects older patients for cytotoxic induction, the impact
of allogeneic transplantation in the present study can only be
assessed for the “best-of-the-worst,” those older patients
whose disease had responded to induction chemotherapy
and who were ﬁt enough to undergo allogeneic trans-
plantation. To be fair, the authors clearly state that theirs is a
report that analyzes age and remission status as it affects the
outcomes of allogeneic transplantation, and it does not
attempt to make a statement about the impact of allogeneic
transplantation on the management of AML in the older
population. In their study, the authors analyzed the outcome
of 48 patients ages  60 among a larger group of patients
undergoing ﬁrst allogeneic transplant for AML in ﬁrst com-
plete remission (CR1) and CR2. Among the older cohort,
preparative conditioning was generally of reduced intensity.
Sixteen older patients underwent transplantation in CR2 and
32 in CR1. Nonrelapse mortality was signiﬁcantly more
common for those who underwent transplantation in CR2
rather than in CR1, but was unacceptably high in both groups
(10 of 16 versus 10 of 32). Although there was no increase in
the hazard ratio for relapse in the CR2 patients, so few were
S.R. Cataland / Biol Blood Marrow Transplant 20 (2014) 437e439438at risk due to treatment-related mortality that such an
analysis is not meaningful.
Themanuscript by the group of investigators fromPrincess
MargaretCancerCentre tellsus that allogeneic transplantation
is feasible for patients over age 60, that treatment-related
mortality can be signiﬁcant, and that long-term survival in a
highly selected group of patients in CR1 may be achieved by
one-third of patients. With such results, were postremission
allogeneic transplantation for all older patients with AML in
CR1 evaluated as a novel therapeutic, I am uncertainwhether
the survival outcome fromdiagnosiswouldwarrant regulatory
approval, as the impact on survival for all would likely be very
limited because so many are excluded at each step of AML
treatment. Does this statement suggest that we not utilize
allogeneic transplantation in older patients? Certainly not.
With sucha limited therapeutic armamentarium,andwith the
sense that biologic factorsmay affect outcome of AML therapy
in the older age population, practitioners must present the
uncertain possibilities of allogeneic transplantation to their
patients, as well as the certainty of unfavorable outcome
associated with so-called conventional therapy.
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Accepted 12 February 2014I read with great interest the report from Jodele et al.
describing the use of eculizumab for the treatment of severe
hematopoietic stem cell transplantationeassociated throm-
botic microangiopathy (HSCT-TMA) [1]. This report extends
the work previously done by this same group of investigators
that reported a high frequency of heterozygous CFHR3-
CFHR1 deletions and associated CFH autoantibodies in
children undergoing allogeneic hematopoietic stem cell
transplantation [2]. In this report, Jodele et al. report the
successful treatment of 4 of 6 pediatric patients with severe
HSCT-TMA characterized by multiorgan impairment, un-
controlled hypertension, and worsening renal function,
despite plasma exchange therapy, that recovered after
treatment with eculizumab, an antibody inhibitor ofterminal complement activity. Although the clinical re-
sponses alone in this cohort of patients are remarkable,
additional data reported in this manuscript, including the
use of total hemolytic complement activity (CH50) to
monitor the effectiveness of therapeutic complement
blockade and the relatively short course of therapy utilized,
are certainly thought provoking. Collectively, both publica-
tions support the hypothesis that complement dysregulation
may be central to the pathogenesis of HSCT-TMA, and they
provide the framework for future studies to better under-
stand the pathophysiology, risk factors, and ultimately the
treatment of HSCT-TMA related to both autologous and
allogeneic stem cell transplantation.
Although the report by Jodele et al. represents a signiﬁ-
cant improvement in our understanding of the pathophysi-
ology of HSCT-TMA, the ﬁndings in this report may
potentially be very important and applicable to other
complement-mediated diseases. There are increasing data to
suggest that the rate of improvement of renal injury in pa-
tients with atypical hemolytic uremic syndrome (aHUS) is
related to the time to initiate therapy with eculizumab, with
a shorter time to the initiation of eculizumab being associ-
ated with greater improvement in renal function [3,4].
However, as pointed out by Jodele et al., it may not be enough
to initiate therapy rapidly; rather, it may be more important
to rapidly achieve therapeutic trough levels of eculizumab
